Dopamine receptors: Functions, subtypes and emerging concepts

Kaiser, Carl; Jain, Tikam C.

doi:10.1002/med.2610050202

Cited by 100 publications

(33 citation statements)

References 556 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although compound 2 contains an aromatic group, it lacks affinity to the DA receptors. This shows that the position of the aromatic ring is also very important, and is in agreement with the suggestion that a distance equivalent to the spacing of two methylene groups in an extended conformation between the phenyl ring and amino group of DA is determinant for dopaminergic activity (21). However, in view of our results and the previous considerations, it is difficult to say whether the presence of the aromatic ring is needed because of sterical requirements or, rather because of electrostatic interactions.…”

Section: Resultssupporting

confidence: 84%

Ade NovoDesign Probe of a Dopamine Receptor Ligand Based on a Theoretical Approach

Bagiński

Claudi²,

Giorgioni³

et al. 1996

Bioorganic Chemistry

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 84%

Ade NovoDesign Probe of a Dopamine Receptor Ligand Based on a Theoretical Approach

Bagiński

Claudi²,

Giorgioni³

et al. 1996

Bioorganic Chemistry

View full text Add to dashboard Cite

“…These drugs interact with D2 dopamine receptors and there is interest in them as potential antipsychotic and anti-Parkinsonian drugs. Like many other drugs, the potency of the 2-aminotetralin derivatives as central nervous system active agents is directly related to their absolute stereochemistry (and conformation) (2,3), which necessitates the preparation of pure enantiomers of the drugs in question. In most instances pure enantiomers have been obtained by resolution of racemic mixtures but the parent compound, (R )-( + )-2-amino-6,7-dihydroxy-l,2,3,4-tetrahydronaphthalene (ADTN), has been recently prepared by a chiral pool synthesis starting from (R)-N-(trifluoroacety1)aspartic anhydride (4).…”

Section: Introductionmentioning

confidence: 99%

An asymmetric synthesis of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN)

Charlton¹,

Koh²,

Plourde³

1990

Can. J. Chem.

View full text Add to dashboard Cite

An asymmetric synthesis of 2-amino-6,7-dimethoxy -1,2,3,4-tetrahydronaphthalene, which can be converted to the title compound by a literature procedure, is described. The synthesis, starting from 2-amino-4,5-dimethoxybenzoic acid and the acrylate of S-methyl lactate, was accomplished in eight steps in 11% overall yield and >97% optical purity.Key words: o-quinodimethanes, Diels-Alder, asymmetric, cycloaddition, induction, diastereoselective, ADTN. Chem. 68, 2028Chem. 68, (1990. On dCcrit une synthkse asymktrique du 2-amino-6,7-dimCthoxy-1,2,3,4-tCtrahydronaphtalkne qui peut Ctre transforme dans le composC mentionnC dans le titre par une procedure dCcrite dans la 1ittCrature. La synthkse, i partir de I'acide 2-amino-4,5-dimCthoxybenzoique et de I'acrylate du lactate de S-mCthyle, a CtC rCalisCe en huit Ctapes, avec un rendement global de 11% et une pureti optique >97%.

show abstract

“…The different behaviour of dopamine vs norepinephrine and epinephrine 30 min after the cold test observed in our controls suggests that circulating dopamine has a role of its own and does not represent a mere reserve for circulating norepinephrine and epinephrine (27); in accord with this, we saw no correlation between the levels of dopamine and those of norepinephrine and epinephrine. Since dopamine has been hypothesized to be involved in vasodilatation (31,32), it is tempting to speculate that circulating dopamine might be a physiological mediator for post-ischaemic vasodilatation. However, because of the variable dopamine increase in controls during the recovery phase, the physiological importance of the small but significantly different dopamine behaviour between patients and controls, which we found in the recovery phase, is still unclear.…”

Section: Discussionmentioning

confidence: 99%

Cold-Induced Changes in Plasma Norepinephrine, Epinephrine and Dopamine Concentrations in Patients with Raynaud's Phenomenon

Marasini

Biondi

Mollica

et al. 1991

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Summary:To investigate the role of the sympathetic System in Raynaud's phenomenon, which has not yet been elucidated, we measured the levels of norepinephrine, epinephrine and dopamine before, immediately and 30 min after the cold pressor test in plasma from 17 patients with primary, 6 with secondary RaynautTs phenomenon and 19 volunteers, matched for age and sex. Patients had significantly low baseline epinephrine (0.13 ± 0.02 vs 0.37 ± 0.04, nmol/1, p < 0.001, mean ± S. E.), but normal norepinephrine and dopamine (norepinephrine: 1.77 ± 0.16 and 2.06 + 0.18; dopamine: 0.10 ± 0.01 and 0.11 + 0.02, patients and controls).Immediately after the cold test norepinephrine significantly increased (p < 0.001) in patients (2.42 + 0.22) and controls (3.24 ± 0.28); epinephrine increased in patients (0.18 ± 0.02, p < 0.02); dopamine did not show any significant change (0.13 ± 0.01 and 0.13 ± 0.02, patients and controls).In the recovery period, while norepinephrine and epinephrine returned to baseline in both groups, dopamine increased in controls (0.21 + 0.04, p < 0.005) but remained unchanged in patients (0.11 ± 0.01).We conclude that there is no sympathetic overactivity in Raynaud's phenomenon and propose a role for circulating dopamine in post-ischaemic vasodilatation äs an explanation for the particular behaviour of dopamine.

show abstract

Dopamine receptors: Functions, subtypes and emerging concepts

Cited by 100 publications

References 556 publications

Ade NovoDesign Probe of a Dopamine Receptor Ligand Based on a Theoretical Approach

Ade NovoDesign Probe of a Dopamine Receptor Ligand Based on a Theoretical Approach

An asymmetric synthesis of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN)

Cold-Induced Changes in Plasma Norepinephrine, Epinephrine and Dopamine Concentrations in Patients with Raynaud's Phenomenon

Contact Info

Product

Resources

About